Cytek Historical Income Statement

CTKB Stock

USD 5.46 0.03 0.55%

Historical analysis of Cytek Biosciences income statement accounts such as Interest Income of 9.2 M, Depreciation And Amortization of 11.1 M or Interest Expense of 1.5 M can show how well Cytek Biosciences performed in making a profits. Evaluating Cytek Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cytek Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cytek Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytek Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

About Cytek Income Statement Analysis

Cytek Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cytek Biosciences shareholders. The income statement also shows Cytek investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cytek Biosciences Income Statement Chart

At present, Cytek Biosciences' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 9.2 M, whereas Tax Provision is forecasted to decline to (1.7 M).

Selling And Marketing Expenses Total Revenue Gross Profit

Total Revenue

Total revenue comprises all receipts Cytek Biosciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Cytek Biosciences minus its cost of goods sold. It is profit before Cytek Biosciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Cytek Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cytek Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.At present, Cytek Biosciences' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 9.2 M, whereas Tax Provision is forecasted to decline to (1.7 M).

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	5.7M	9.2M	10.6M	11.1M
Interest Income	4.6M	7.6M	8.7M	9.2M

Depreciation And Amortization Interest Income

Cytek Biosciences income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other
Tax Provision		-0.42	-0.45	-0.48	-0.38	-0.43	-0.45	-0.5	-0.49	-0.46	0.29	-0.66	0.14	-0.45	-0.11	-0.51	-0.44	-0.48	-0.56	-0.68	-0.68	0.96	-0.48
Net Interest Income	-0.42		0.97	0.93	0.6	0.75	0.77	0.72	0.69	0.76	-0.96	-0.19	-0.94	0.75	-0.81	0.77	0.76	0.93	-0.28	0.74	-0.14	-0.64	0.91
Interest Income	-0.45	0.97		0.99	0.77	0.87	0.87	0.85	0.83	0.87	-0.96	-0.02	-0.9	0.86	-0.71	0.87	0.87	0.99	-0.09	0.86	0.04	-0.67	0.97
Depreciation And Amortization	-0.48	0.93	0.99		0.83	0.9	0.9	0.9	0.88	0.9	-0.94	0.08	-0.86	0.9	-0.64	0.91	0.9	1.0	0.01	0.91	0.14	-0.69	0.98
Interest Expense	-0.38	0.6	0.77	0.83		0.95	0.92	0.96	0.98	0.93	-0.69	0.4	-0.54	0.95	-0.24	0.92	0.94	0.83	0.38	0.89	0.44	-0.53	0.86
Selling General Administrative	-0.43	0.75	0.87	0.9	0.95		0.99	0.99	0.98	1.0	-0.83	0.23	-0.71	1.0	-0.45	0.99	1.0	0.9	0.18	0.89	0.28	-0.62	0.9
Selling And Marketing Expenses	-0.45	0.77	0.87	0.9	0.92	0.99		0.99	0.97	1.0	-0.85	0.21	-0.74	1.0	-0.48	1.0	1.0	0.9	0.16	0.89	0.27	-0.65	0.88
Total Revenue	-0.5	0.72	0.85	0.9	0.96	0.99	0.99		1.0	0.99	-0.79	0.34	-0.66	1.0	-0.38	0.99	0.99	0.9	0.29	0.93	0.39	-0.67	0.89
Gross Profit	-0.49	0.69	0.83	0.88	0.98	0.98	0.97	1.0		0.98	-0.76	0.38	-0.62	0.99	-0.32	0.98	0.98	0.88	0.34	0.94	0.43	-0.65	0.88
Other Operating Expenses	-0.46	0.76	0.87	0.9	0.93	1.0	1.0	0.99	0.98		-0.84	0.24	-0.72	1.0	-0.46	1.0	1.0	0.91	0.19	0.9	0.29	-0.66	0.89
Operating Income	0.29	-0.96	-0.96	-0.94	-0.69	-0.83	-0.85	-0.79	-0.76	-0.84		0.21	0.98	-0.82	0.84	-0.84	-0.83	-0.94	0.27	-0.76	0.15	0.55	-0.89
Net Income From Continuing Ops	-0.66	-0.19	-0.02	0.08	0.4	0.23	0.21	0.34	0.38	0.24	0.21		0.41	0.26	0.69	0.26	0.23	0.09	0.99	0.47	1.0	-0.51	0.11
Ebit	0.14	-0.94	-0.9	-0.86	-0.54	-0.71	-0.74	-0.66	-0.62	-0.72	0.98	0.41		-0.7	0.94	-0.72	-0.72	-0.86	0.47	-0.61	0.35	0.42	-0.81
Research Development	-0.45	0.75	0.86	0.9	0.95	1.0	1.0	1.0	0.99	1.0	-0.82	0.26	-0.7		-0.43	0.99	1.0	0.9	0.21	0.91	0.31	-0.64	0.9
Ebitda	-0.11	-0.81	-0.71	-0.64	-0.24	-0.45	-0.48	-0.38	-0.32	-0.46	0.84	0.69	0.94	-0.43		-0.46	-0.46	-0.63	0.74	-0.31	0.64	0.17	-0.56
Cost Of Revenue	-0.51	0.77	0.87	0.91	0.92	0.99	1.0	0.99	0.98	1.0	-0.84	0.26	-0.72	0.99	-0.46		1.0	0.91	0.2	0.92	0.31	-0.69	0.89
Total Operating Expenses	-0.44	0.76	0.87	0.9	0.94	1.0	1.0	0.99	0.98	1.0	-0.83	0.23	-0.72	1.0	-0.46	1.0		0.9	0.18	0.9	0.28	-0.64	0.89
Reconciled Depreciation	-0.48	0.93	0.99	1.0	0.83	0.9	0.9	0.9	0.88	0.91	-0.94	0.09	-0.86	0.9	-0.63	0.91	0.9		0.02	0.91	0.15	-0.69	0.98
Income Before Tax	-0.56	-0.28	-0.09	0.01	0.38	0.18	0.16	0.29	0.34	0.19	0.27	0.99	0.47	0.21	0.74	0.2	0.18	0.02		0.41	0.99	-0.4	0.05
Total Other Income Expense Net	-0.68	0.74	0.86	0.91	0.89	0.89	0.89	0.93	0.94	0.9	-0.76	0.47	-0.61	0.91	-0.31	0.92	0.9	0.91	0.41		0.53	-0.82	0.89
Net Income	-0.68	-0.14	0.04	0.14	0.44	0.28	0.27	0.39	0.43	0.29	0.15	1.0	0.35	0.31	0.64	0.31	0.28	0.15	0.99	0.53		-0.55	0.17
Income Tax Expense	0.96	-0.64	-0.67	-0.69	-0.53	-0.62	-0.65	-0.67	-0.65	-0.66	0.55	-0.51	0.42	-0.64	0.17	-0.69	-0.64	-0.69	-0.4	-0.82	-0.55		-0.67
Non Operating Income Net Other	-0.48	0.91	0.97	0.98	0.86	0.9	0.88	0.89	0.88	0.89	-0.89	0.11	-0.81	0.9	-0.56	0.89	0.89	0.98	0.05	0.89	0.17	-0.67

Click cells to compare fundamentals

Cytek Biosciences Account Relationship Matchups

Cytek Biosciences income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Tax Provision	(5.0M)	1.5M	(1.2M)	(1.8M)	(1.6M)	(1.7M)
Net Interest Income	(223K)	(1.7M)	2.0M	5.2M	6.0M	6.3M
Interest Income	110K	49K	4.6M	7.6M	8.7M	9.2M
Depreciation And Amortization	603K	1.2M	5.7M	9.2M	10.6M	11.1M
Interest Expense	333K	1.7M	2.6M	2.1M	2.4M	1.5M
Selling General Administrative	9.4M	20.8M	34.7M	42.5M	48.8M	25.1M
Selling And Marketing Expenses	15.0M	24.7M	33.2M	49.1M	56.5M	29.1M
Total Revenue	92.8M	128.0M	164.0M	193.0M	222.0M	139.9M
Gross Profit	51.7M	79.1M	101.0M	109.4M	125.8M	81.4M
Other Operating Expenses	79.2M	118.8M	165.8M	220.9M	254.0M	140.8M
Operating Income	13.7M	6.4M	(1.8M)	(27.8M)	(25.1M)	(23.8M)
Net Income From Continuing Ops	19.4M	4.4M	2.5M	(13.9M)	(12.5M)	(11.9M)
Ebit	14.8M	9.2M	3.8M	(13.6M)	(12.3M)	(11.7M)
Research Development	13.7M	24.4M	34.9M	44.2M	50.8M	27.7M
Ebitda	15.4M	10.4M	9.5M	(4.4M)	(4.0M)	(3.8M)
Cost Of Revenue	41.1M	48.8M	63.1M	83.6M	96.1M	58.5M
Total Operating Expenses	38.1M	70.0M	102.8M	137.3M	157.9M	82.3M
Reconciled Depreciation	603K	1.2M	5.7M	8.7M	10.0M	10.5M
Income Before Tax	14.4M	5.9M	1.3M	(15.7M)	(14.1M)	(13.4M)
Total Other Income Expense Net	771K	(3.2M)	3.1M	12.1M	14.0M	14.7M
Net Income	19.4M	4.4M	2.6M	(12.1M)	(10.9M)	(10.4M)
Income Tax Expense	(5.0M)	1.5M	(1.2M)	(3.6M)	(3.2M)	(3.0M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:

How To Invest In Cytek

Details

Is Cytek Stock a good investment?

Details

What is Cytek Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.658

Earnings Share

(0.08)

Revenue Per Share

1.527

Quarterly Revenue Growth

0.073

Return On Assets

(0.03)

The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytek Historical Income Statement

About Cytek Income Statement Analysis

Cytek Biosciences Income Statement Chart

Total Revenue

Gross Profit

Cytek Biosciences income statement Correlations

Cytek Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytek Biosciences income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Other Operating Expenses	+ 1.0	Selling And Marketing Expenses
Research Development	+ 1.0	Selling And Marketing Expenses

Operating Income	- 0.96	Interest Income
Operating Income	- 0.96	Net Interest Income
Reconciled Depreciation	- 0.94	Operating Income
Operating Income	- 0.94	Depreciation And Amortization
Ebit	- 0.94	Net Interest Income
Ebit	- 0.9	Interest Income